Showing results (1471-1480 of 1,985) with videos related to

Sort By:
Pageof 199
The Lancet. Neurology|July 19, 2025
Focused ultrasound therapy for movement disordersRaúl Martínez-Fernández, Steffen Paschen, Marta Del Álamo, et al.
The Lancet. Neurology|July 19, 2025
α-synuclein biomarker assays: bridging research and patient careJulian Agin-Liebes, Alexandra Lodge, Hasini Reddy, et al.
The Lancet. Neurology|July 19, 2025
Acute-onset axonal neuropathy following infection in children with biallelic RCC1 variants: a case seriesJ Robert Harkness, John H McDermott, Shea Marsden, et al.
The Lancet. Neurology|September 20, 2025
2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosisFrederik Barkhof, Daniel S Reich, Jiwon Oh, et al.
The Lancet. Neurology|September 20, 2025
Association between the Edinburgh CT and genetic diagnostic criteria for cerebral amyloid angiopathy-associated lobar intracerebral haemorrhage and recurrent intracerebral haemorrhage: an individual patient data meta-analysisMark A Rodrigues, David Seiffge, Neshika Samarasekera, et al.
The Lancet. Neurology|February 16, 2024
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort studyPushpa Narayanaswami, Donald B Sanders, Laine Thomas, et al.
The Lancet. Neurology|March 18, 2024
Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trialAlberto J Espay, Fabrizio Stocchi, Rajesh Pahwa, et al.
The Lancet. Neurology|March 20, 2024
Dysphagia after stroke: research advances in treatment interventionsBendix Labeit, Emilia Michou, Michaela Trapl-Grundschober, et al.
The Lancet. Neurology|September 14, 2024
Frailty for neurologists: perspectives on how frailty influences care planningMarco Canevelli, Caitlin Jackson-Tarlton, Kenneth Rockwood
The Lancet. Neurology|September 20, 2024
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trialJeffrey A Allen, Jie Lin, Ivana Basta, et al.
Pageof 199